Safety and efficacy of vortioxetine on depressive symptoms and cognition in post-stroke patients: a pilot study

G Gamberini, F G Masuccio, G Ferriero, D Cattaneo, C Solaro

Research output: Contribution to journalArticlepeer-review

Abstract

The development of post-stroke depression (PSD) is the most frequent neuropsychiatric complication after stroke with an estimated prevalence between 18 and 33% . Vortioxetine, a novel multimodal antidepressant, demonstrated no interaction-induced adverse events when associated with others drugs, without influence on QTc and blood pressure in elderly patients. In a meta-analysis, the effects of vortioxetine on cognitive functions in subjects with major depressive disorders have been high-lighted, although no studies in the English literature have examined its safety and efficacy on PSD in stroke survivors. The aim of the study is to evaluate the safety of vortioxetine and the effects on PSD and cognition in subacute stroke survivors.
Original languageEnglish
Pages (from-to)108-109
Number of pages2
JournalJournal of Affective Disorders
Volume286
DOIs
Publication statusPublished - May 1 2021

Keywords

  • Cognition
  • Depression/drug therapy
  • Double-Blind Method
  • Humans
  • Pilot Projects
  • Serotonin Uptake Inhibitors
  • Stroke/complications
  • Sulfides
  • Vortioxetine

Fingerprint

Dive into the research topics of 'Safety and efficacy of vortioxetine on depressive symptoms and cognition in post-stroke patients: a pilot study'. Together they form a unique fingerprint.

Cite this